COVID-19 may predispose to both venous and arterial thromboembolic disease due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation (DIC) \[[@bb0005], [@bb0010], [@bb0015], [@bb0020]\]. Remarkably, thrombotic complications have hardly been described \[[@bb0005], [@bb0010], [@bb0015], [@bb0020]\]. Precise knowledge of the incidence of thrombotic complications in COVID-19 patients is important for decision making with regard to intensity of thromboprophylaxis, especially in patients admitted to the intensive care unit (ICU) who are at highest thrombotic risk.

We evaluated the incidence of the composite outcome of venous thromboembolism (VTE) and arterial thrombotic complications in all COVID-19 patients admitted to the ICU of 2 Dutch university hospitals and 1 Dutch teaching hospital. Our composite outcome consisted of acute pulmonary embolism (PE), deep-vein thrombosis (DVT), ischemic stroke, myocardial infarction or systemic arterial embolism. Importantly, in all participating hospitals, diagnostic tests were only applied if thrombotic complications were clinically suspected. We calculated the cumulative incidence of the composite outcome, as well as for the venous and arterial thrombotic complications separately. The index date was the moment of ICU admission. Patients were followed until ICU discharge, until they died, or until April 5th 2020, whichever came first. We performed backward conditional regression analyses to identify relevant determinants. The Institutional Review Boards of the participating hospitals waived the need for informed consent due to the observational nature of our study.

We studied 184 patients with proven COVID-19 pneumonia ([Table 1](#t0005){ref-type="table"} ) admitted to the ICU between March 7th and April 5th 2020. Of those, 23 died (13%), 22 were discharged alive (12%) and 139 (76%) were still on the ICU on April 5th 2020. The median duration of the observation per patient was 7 days (IQR 1-13). All patients received at least standard doses thromboprophylaxis, although regimens differed between hospitals and doses increased over time ([Table 2](#t0010){ref-type="table"} ). The cumulative incidence of the composite outcome was 31% (95%CI 20-41%; [Fig. 1](#f0005){ref-type="fig"} , [Table 3](#t0015){ref-type="table"} ), of which CTPA and/or ultrasonography confirmed VTE in 27% (95%CI 17-37%) and arterial thrombotic events in 3.7% (95%CI 0-8.2%). PE was the most frequent thrombotic complication (*n* = 25, 81%). Age (adjusted hazard ratio (aHR) 1.05/per year, 95%CI 1.004-1.01) and coagulopathy, defined as spontaneous prolongation of the prothrombin time \> 3 s or activated partial thromboplastin time \> 5 s (aHR 4.1, 95%CI 1.9-9.1), were independent predictors of thrombotic complications.Table 1Characteristics of included patients.Table 1Age (Mean, standard deviation)64 (12)Male sex (number, %)139 (76)Body weight (mean, standard deviation)87 (16)Active cancer (number, %)5 (2.7)Coagulopathy during admission[a](#tf0005){ref-type="table-fn"} (n, %)70 (38)Therapeutic anticoagulation at admission (n, %)17 (9.2)Renal replacement therapy during admission (n, %)23 (13%)[^2]Table 2Local protocol for thromboprophylaxis in participating centres for patients admitted to the intensive care unit during the study period.Table 2SiteLeiden University Medical Centernadroparin 2850 IU sc per day or 5700 IU per day if body weight \> 100 kgErasmus University Medical CenterNadroparin 5700 IU per day; nadroparin 5700 IU sc twice daily from April 4th 2020 and onwardsAmphia Hospital BredaNadroparin 2850 IU sc per day or 5700 IU per day if body weight \> 100 kg;\
nadroparin 5700 IU sc per day from March 30th 2020 and onwardsFig. 1Cumulative incidence of venous and arterial thrombotic complications during the course of intensive care unit admission of patients with proven COVID-19 pneumonia.Fig. 1Table 3Description of thrombotic complications.Table 3Type of eventNumber of casesRelevant detailsPulmonary embolism25−18 cases with at least PE in segmental arteries, 7 cases PE limited to subsegmental arteriesOther venous thromboembolic events3−1 proximal deep-vein thrombosis of the leg−2 catheter related upper extremity thrombosisArterial thrombotic events3−All ischemic strokes[^3]

Despite systematic thrombosis prophylaxis, the 31% incidence of thrombotic complications in ICU patients with COVID-19 infections is remarkably high and well comparable to the VTE incidence in other patient categories with overt DIC \[[@bb0025]\]. Notably, none of our patients actually developed DIC.

What are the consequences of our observations? First, they represent a conservative estimation, because the majority of patients was still on the ICU and therefore at risk after the described observation period. Also, VTE is more difficult to recognize in intubated patients with a higher threshold to perform diagnostic imaging tests because of strict isolation. If VTE screening had been applied, the incidence could have been even higher. We have to acknowledge that due to the design of the study, we could not adjust our findings for the actual administered doses of nadroparin, nor study the effect of the changes in the local protocols for thromboprophylaxis indicated in [Table 2](#t0010){ref-type="table"}. In view of this, our findings reinforce the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are suggestive of increasing the prophylaxis towards high-prophylactic doses, e.g. going from enoxaparin 40 mg OD to 40 mg BID, even in the absence of randomized evidence.

Finally, we propose that, rather than treating all patients with COVID-19 infections at the ICU with therapeutic anticoagulation, physicians should be vigilant for signs of thrombotic complications, and order appropriate diagnostic tests at a low threshold \[[@bb0025]\].
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[^1]: qually contributed as senior authors.

[^2]: Defined as: spontaneous prolongation of the prothrombin time (PT) \>3 s or activated partial thromboplastin time (APTT) \> 5 s.

[^3]: Note: acute pulmonary embolism was diagnosed with CT-pulmonary angiography, deep vein thrombosis/upper extremity vein thrombosis was diagnosed with ultrasonography, strokes were diagnosed with CT.
